PBS updates

Repatha (Evolocumab)

evolocumab 140 mg/mL injection, 1 mL pen device · INJECTION · PBS code 11985T

STREAMLINED

What it costs

AU$190 PBS-determined price per 2 units

Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.

  • • First listed on the PBS: 2020-05-01.
  • • Repeats: 5.
  • • PBS program: GE.
Eligibility criteria for subsidised access

The following is the government's own wording from the PBS Schedule, shown unchanged.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Non-familial hypercholesterolaemia


Continuing treatment with this drug or switching treatment from any of: (i) another drug that belongs to the same pharmacological class as this drug, (ii) inclisiran


Patient must have previously received PBS-subsidised treatment with this drug for this condition; or

Patient must have received PBS-subsidised treatment for this PBS indication with any of: (i) a drug from the same pharmacological class as this drug (ii) inclisiran; AND

The treatment must be in conjunction with dietary therapy and exercise; AND

Patient must not be receiving concomitant PBS-subsidised treatment with any of: (i) another drug that belongs to the same pharmacological class as this drug, (ii) inclisiran, for this PBS indication; AND

Must be treated by a medical practitioner; or

Must be treated by a nurse practitioner in consultation with a specialist physician.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Familial heterozygous hypercholesterolaemia


Continuing treatment with this drug or switching treatment from any of: (i) another drug that belongs to the same pharmacological class as this drug, (ii) inclisiran


Patient must have previously received PBS-subsidised treatment with this drug for this condition; or

Patient must have received PBS-subsidised treatment for this PBS indication with any of: (i) a drug from the same pharmacological class as this drug (ii) inclisiran; AND

The treatment must be in conjunction with dietary therapy and exercise; AND

Patient must not be receiving concomitant PBS-subsidised treatment with any of: (i) another drug that belongs to the same pharmacological class as this drug, (ii) inclisiran, for this PBS indication; AND

Must be treated by a medical practitioner; or

Must be treated by a nurse practitioner in consultation with a specialist physician.

Sponsor: Amgen Australia Pty Limited ABN 31 051 057 428

Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.